Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0W4ZU
|
|||
Former ID |
DNC012053
|
|||
Drug Name |
KURARINOL
|
|||
Synonyms |
Kurarinol; CHEBI:81093; 855746-98-4; CHEMBL455667; MolPort-039-338-650; ZINC13817026; BDBM50366788; C17444
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C26H32O7
|
|||
Canonical SMILES |
CC(=C)C(CCC(C)(C)O)CC1=C2C(=C(C=C1O)OC)C(=O)CC(O2)C3=C(C=C(C=C3)O)O
|
|||
InChI |
1S/C26H32O7/c1-14(2)15(8-9-26(3,4)31)10-18-20(29)12-23(32-5)24-21(30)13-22(33-25(18)24)17-7-6-16(27)11-19(17)28/h6-7,11-12,15,22,27-29,31H,1,8-10,13H2,2-5H3/t15-,22+/m1/s1
|
|||
InChIKey |
XMUPAAIHKAIUSU-QRQCRPRQSA-N
|
|||
CAS Number |
CAS 855746-98-4
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:81093
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Phosphodiesterase 3A (PDE3A) | Target Info | Inhibitor | [1] |
Phosphodiesterase 4A (PDE4A) | Target Info | Inhibitor | [1] | |
Phosphodiesterase 4B (PDE4B) | Target Info | Inhibitor | [1] | |
Phosphodiesterase 5A (PDE5A) | Target Info | Inhibitor | [1] | |
KEGG Pathway | Purine metabolism | |||
cAMP signaling pathway | ||||
Morphine addiction | ||||
cGMP-PKG signaling pathway | ||||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
IL5 Signaling Pathway | ||||
IL2 Signaling Pathway | ||||
Reactome | DARPP-32 events | |||
G alpha (s) signalling events | ||||
cGMP effects | ||||
WikiPathways | G Protein Signaling Pathways | |||
miR-targeted genes in muscle cell - TarBase | ||||
miR-targeted genes in lymphocytes - TarBase | ||||
Myometrial Relaxation and Contraction Pathways | ||||
Nuclear Receptors Meta-Pathway | ||||
Opioid Signalling |
References | Top | |||
---|---|---|---|---|
REF 1 | A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.